Clinical trial
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic…
NCT00126321 · University Hospital, Bonn, Other · Unknown status
Key facts
| NCT number | NCT00126321 |
|---|---|
| Title | Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML) |
| Official title | Phase II Study of Cladribine, High-dose Cytarabine and Idarubicin in Patients With Relapsed Acute Myeloid Leukemia |
| Lead sponsor | University Hospital, Bonn, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelocytic, Acute |
| Intervention type | Drug |
| Interventions | cladribine |
| Enrollment | 50 |
| Start date | Nov 1, 2004 |
| Primary completion | Nov 1, 2010 |
| Completion | Mar 1, 2011 |
| First posted | Aug 3, 2005 |
| Last update posted | Feb 2, 2010 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: